Review
Molecular signatures from omics data: From chaos to consensus
Article first published online: 23 APR 2012
DOI: 10.1002/biot.201100305
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Issue

Biotechnology Journal
Special Issue: Focus: Systems biology and personalized medicine
Volume 7, Issue 8, pages 946–957, August 2012
Additional Information
How to Cite
Sung, J., Wang, Y., Chandrasekaran, S., Witten, D. M. and Price, N. D. (2012), Molecular signatures from omics data: From chaos to consensus. Biotechnology Journal, 7: 946–957. doi: 10.1002/biot.201100305
Publication History
- Issue published online: 6 AUG 2012
- Article first published online: 23 APR 2012
- Manuscript Accepted: 8 MAR 2012
- Manuscript Revised: 14 FEB 2012
- Manuscript Received: 9 DEC 2011
Funded by
- NIH/NCI Howard Temin Pathway to Independence Award in Cancer Research
- Roy J. Carver Young Investigator Grant
- Grand Duchy of Luxembourg-Institute for Systems Biology Consortium
- Camille Dreyfus Teacher-Scholar Program (NDP)
- HHMI Pre-Doctoral Fellowship (SC)
- NIH Director's Early Independence Award. Grant Number: DW DP5OD009145
- Funded Access
- Abstract
- Article
- References
- Cited By
Keywords:
- Diagnostics;
- Disease classification;
- Systems biology;
- Translational bioinformatics
Abstract
In the past 15 years, new “omics” technologies have made it possible to obtain high-resolution molecular snapshots of organisms, tissues, and even individual cells at various disease states and experimental conditions. It is hoped that these developments will usher in a new era of personalized medicine in which an individual's molecular measurements are used to diagnose disease, guide therapy, and perform other tasks more accurately and effectively than is possible using standard approaches. There now exists a vast literature of reported “molecular signatures”. However, despite some notable exceptions, many of these signatures have suffered from limited reproducibility in independent datasets, insufficient sensitivity or specificity to meet clinical needs, or other challenges. In this paper, we discuss the process of molecular signature discovery on the basis of omics data. In particular, we highlight potential pitfalls in the discovery process, as well as strategies that can be used to increase the odds of successful discovery. Despite the difficulties that have plagued the field of molecular signature discovery, we remain optimistic about the potential to harness the vast amounts of available omics data in order to substantially impact clinical practice.

1860-7314/asset/olbannerleft.gif?v=1&s=da6370bb70a3504eb7effce9aef3fb1f84c5d314)